Clinical Traceability: From Source Data to Submission

Clinical traceability is the ability to follow clinical evidence from its original source through processing, analysis and reporting, and to reconstruct that path when a question arises. It applies to clinical data, the scientific conclusions drawn from those data and the investigational products and other materials used during a trial. This matters because clinical information rarely remains within one system or organisation. Data may pass through sites, laboratories, technology providers, contract research organisations (CROs) and sponsor teams before appearing in an analysis, Clinical Study Report (CSR) or regulatory submission. Clinical trial materials may follow an equally complex physical route from sourcing and packaging to shipment, dispensing, return and destruction.

In Brief

• Clinical traceability links to source data, transformations, analyses, and reported conclusions so the evidence behind a result can be constructed.
• It supports regulatory review, discrepancy investigation, study transfer, and the long-term use of clinical information.
• Operationally, it spans SDTM and ADaM datasets, statistical outputs, metadata, audit trails, and the custody chain for trial materials.
• Technology can support traceability, but incomplete metadata, manual transfers, migrations, and unclear ownership can still break the chain.
• The practical test is whether teams can identify, explain, and review the data, decisions, and materials behind a clinical trial result.
  

What is clinical traceability?

Clinical traceability means being able to identify the origin of a clinical data point or trial material, follow what happened to it, and understand how it contributed to a reported result or decision.

For clinical information, traceability means knowing where your data are located, how information is derived and from which data. At study level, this includes the path from source records and collected observations through tabulation datasets, analysis datasets, statistical outputs, and the conclusions reported in the CSR. At a programme level, it includes the evidence and reasoning used to support regulatory decisions, labelling claims, and later changes to a product’s use.

Scientific traceability is the ability to reconstruct the evidence behind a scientific conclusion. For example, a reviewer should be able to move from a reported treatment effect or p-value back through the statistical method, analysis variables and source observations used to produce it. A traceable result is therefore more than a number stored in the correct location. Its origin, meaning, derivation, and context must remain understandable.

The aim is to maintain an authoritative and reviewable information trail across the systems and organisations involved.

Why is clinical traceability important?

The way a sponsor creates, stores, and retrieves clinical information affects the reviewability of its evidence and its ability to investigate questions throughout the product lifecycle. Traceability is easier to establish prospectively than to reconstruct during a submission or inspection.

Clinical teams may focus on the next database lock, analysis or submission milestone, but the supporting evidence may be needed many years later. Regulatory authorities, internal governance teams or future development partners may need to understand what was collected, how it was processed and why a particular conclusion was reached.

Traceability has practical value when teams need to:

• reproduce or explain a statistical result

• investigate an unexpected value or discrepancy
• assess the effect of a data or programming change
• respond to a regulatory question
• transfer a study between systems, CROs, or sponsors
• combine information across several studies
• confirm the identity, condition, and disposition of clinical trial materials

These need to persist from first-in-human development through submission, post-authorisation activity and the eventual discontinuation or withdrawal of a product. Over that period, standards, systems, suppliers and organisational ownership may all change.

How does clinical data move from source to submission?

A typical traceability path may include:

1. Source records, laboratory results, eCOA, device data, or other original observations
2. Data entered or transferred into an EDC system or clinical data management system
3. Data cleaning, coding, reconciliation, and query management
4. SDTM datasets need to organise collected study data
5. ADaM datasets containing analysis-ready variables and documented derivations
6. TLFs, statistical analyses, and supporting programs
7. The CSR, submission summaries, and other regulatory documents

A reviewer moving backwards through this path should be able to identify which analysis dataset and variables supported a result, how those variables were derived, which tabulation records they came from and where the original observations were collected.

The same principle applies to information repeated across the statistical analysis plan (SAP), TLFs, CSR and Common Technical Document summaries. Reuse can reduce manual copying, but only when the reused result remains connected to its analysis definition, input data, program version and approval history.

A p-value copied into several documents is not inherently traceable. The traceable information includes the endpoint definition, population, statistical method, analysis variables, source records, program and output version from which that p-value was obtained.

Important scientific and operational decisions also need sufficient documentation. This may include reasons for selecting an analysis population, handling missing data, changing a derivation or excluding a record. Recording the rationale at the time is usually more reliable than attempting to reconstruct it later.

What standards and metadata support clinical traceability?

Common standards and metadata provide continuity across this variable environment. They define what a data element means, where it came from, how it was transformed and how it relates to other records.

Relevant components may include:

• CDASH conventions for data collection

• annotated CRFs linking collection fields to SDTM variables
• SDTM datasets and controlled terminology
• ADaM datasets with source-variable and derivation traceability
• Define-XML describing dataset and variable metadata
• analysis results metadata linking outputs to analysis datasets and methods
• study data and analysis data reviewer's guides
• data specifications, transfer agreements, and transformation rules
• retained programs,  logs, version histories, and approval records

These components do not need to sit in the same application, but their relationships should be controlled and understandable. CDISC conformance is an important part of this work, although passing structural conformance checks does not by itself demonstrate that the complete path from source data to each reported result can be reconstructed.

How can clinical traceability be checked and visualised?

Traceability becomes difficult when an important figure exists only inside an output, spreadsheet or Word document, or when results are transferred manually between environments. Multiple copies can then exist without an obvious connection to the approved source or analysis version.

Where practical, documents should consume controlled results rather than become the only location in which those results exist. Metadata can link a statement or output to the underlying analysis, data and program without requiring all content to be stored in one platform.

Metadata relationship maps can also show how data move through the study. A team may use forward tracing to identify which outputs depend on a particular source variable, or reverse tracing to identify the source records and derivations behind a reported result. Computable metadata can support queries, visual lineage maps and automated checks for missing relationships. Research into graph-based traceability has shown how metadata models can be used to identify gaps and visualise relationships across the clinical data lifecycle. These tools can make review more efficient, but their usefulness depends on the completeness and quality of the metadata entered.

How are clinical trial materials traced from sourcing to disposition?

Traceability in a clinical trial also applies to physical materials, including active pharmaceutical ingredients (APIs), comparator products, investigational medicinal products, kits, devices and biological samples.

The required chain will vary study by study, but investigational-product traceability may cover:

• API and comparator sourcing

• manufacture and release
• packaging, labelling, and serialisation
• depot and site inventory
• shipment and receipt
• storage conditions
• randomisation and kit assignment 
• dispensing or administration
• returns, reconciliation, and destruction

Each stage should retain enough information to identify the material, its batch or kit, its location, its status and the relevant transfer of responsibility. Where storage conditions are important, the traceability record may also need to include temperature excursions or other environmental information.

The physical and digital records need to remain connected. A system may show that a kit was allocated to a participant, for example, while pharmacy, dispensing or administration records confirm what occurred at the site. Reconciliation between these records helps identify missing, duplicated or inconsistent transactions.

What technologies ensure traceability of clinical trial materials?

No single technology ensures traceability of clinical trial materials. Technologies support traceability when they are configured for the study, used consistently and backed by controlled processes, reconciliation and oversight.

Technologies for traceability of clinical trial materials may include:

Interactive response technology (IRT) and randomisation and trial supply management (RTSM)
IRT or RTSM systems can manage kit allocation, randomisation, resupply, dispensing, and inventory status. They help connect participants, sites and kit identifiers while maintaining the study blind where required.

Inventory and warehouse management systems
Inventory platforms can track quantities, batches, expiry dates, locations and movements between manufacturing sites, depots, and trial sites. Interfaces with IRT or RTSM systems can reduce duplicate entry, but transferred records still need reconciliation.

Serialisation and barcode scanning
Unique serial numbers, two-dimensional barcodes or radio-frequency identification can associate a physical pack or kit with its electronic record. Scanning can reduce manual transcription during packaging, receipt, dispensing, return and destruction.

Smart packaging and connected sensors
These can record events such as pack opening, location or environmental conditions. Temperature and humidity monitors can support assessments of whether materials remained within specified storage and transport conditions.

Distributed-ledger technology
A permissioned distributed ledger, sometimes described as a private blockchain, may be considered where several organisations need access to a shared, tamper-evident transaction history. It is one possible architecture rather than a general requirement, and it does not replace validation, governance, access controls or reconciliation.

Technology selection should therefore begin with the material risks, trial design, custody chain and information that must be reconstructed. A complex platform adds little value if kit identifiers, transfer records or responsibilities are poorly defined.

What governance is needed across sponsors, CROs, and systems?

Clinical traceability does not depend on using one CRO, technology provider or central repository. A sponsor may use different specialist providers across a development programme while retaining a consistent traceability framework.

That framework should define:

• which organisation owns each data, document, and material record

• which standards, terminology, and metadata conventions apply
• how information is transferred between systems
• how transfers and reconciliations are checked
• how versions, corrections, and transformations are documented
• which records must be retained and for how long
• who reviews traceability and resolves gaps
• how access, security, and audit trails are controlled

Activities may be transferred to CROs, labs or technology vendors, but sponsor oversight remains necessary. Agreements should describe responsibilities clearly enough that there is no gap between contractual ownership, system access and operational practice. 

Where does clinical traceability break down?

Common failure points include:

• derivations that are coded but not adequately specified

• missing source-variable references in analysis metadata
• external data received without complete transfer specifications
• inconsistent identifiers across systems
• unreconciled differences between IRT, pharmacy, and clinical data
• programs or logs that are overwritten or not retained
• systems migrations that omit metadata or audit history
• legacy-data conversions with incomplete mappings
• provider transitions where assumptions and decisions are not transferred

Legacy conversion is a particular risk because data may be moved into a new structure long after the original collection and processing decisions were made. Conversion plans should document mapping rules, known limitations, checks performed and the relationship between the legacy and converted records.

What do current regulations and guidance expect?

Regulatory frameworks generally focus on whether clinical trial information and materials remain accurate, complete, attributable and capable of being reconstructed. They do not prescribe one universal traceability platform.

In the UK, the Medicines for Human Use (Clinical Trials) Regulations 2004 have been amended, with the revised framework taking full effect on 28 April 2026. References to the original 2004 provisions should therefore be checked against the amended regulations and applicable transitional arrangements.

ICH E6(R3), adopted at Step 4 in January 2025, places increased emphasis on proportionate data governance across the full data lifecycle. Its expectations include appropriate controls for data acquisition, transformations, transfers, migrations, corrections, review, finalisation and retention. The guideline also makes clear that transferred activities remain subject to sponsor oversight.

For submissions to the US Food and Drug Administration, the June 2026 Study Data Technical Conformance Guide provides current technical recommendations on standardised study data. Its coverage includes study-data validation, provenance, traceability, reviewer documentation and legacy-data conversion.

These frameworks should be interpreted alongside the requirements that apply to the study, jurisdiction, product and data source. Traceability controls should remain proportionate to the importance of the data and the risks to participant protection and the reliability of trial results.

Conclusion

The practical aim of clinical traceability is to ensure that questions can be answered using evidence and materials that remains identifiable, reconstructable, and reviewable. This requires prospective planning, controlled standards, complete metadata, suitable technologies, and clear governance across every organisation involved in the trial.

Need support building clinical traceability across data, analyses, systems, and trial materials? Quanticate helps sponsors establish clear standards, metadata, governance, and delivery processes that make clinical information easier to track, review, and explain across the development lifecycle. Request a consultation and a member of our team will be in touch.